CDT shares plunged roughly -32% to $0.0818 from the prior session's $0.121 close, extending heavy losses. The move began in premarket trading (down ~-27% to $0.08) and carried through the regular session.
BRVE slid roughly -8% in regular trading, last near $21.50 versus a $23.37 prior close. The decline unwinds most of yesterday's +8.9% rebound as the recently listed biotech gives back gains.
KRSA closed up +15.14% (+$4.89) at $37.19 during regular trading, versus a $32.30 prior close. Volume surged to roughly 411,000 shares, about 28x its ~15,000-share average, indicating heavy buying interest.
Dyne Therapeutics (DYN) shares fell roughly 37% over the last 30 days, declining from about $26.34 to $16.51. The sharp selloff was triggered by Novartis (NVS) reporting a Phase 3 failure for del-desiran in myotonic dystrophy type 1 (DM1), rattling the broader muscle-disease drug sector.
Prime Medicine (PRME) shares fell roughly 14% over the trailing 30 days, from a close of $3.58 on August 26, 2026 to $3.07 on September 24, 2026. The decline occurred despite a steady stream of pipeline milestones, underscoring ongoing volatility and selling pressure across the gene-editing sector.
ZBIO fell -9.96% during regular trading hours to roughly $26.68, down from the prior session's close of $29.63. The primary catalyst was a newly filed shelf registration covering up to 7 million shares, stoking dilution fears among holders.
VKTX is down -11.33% to $36.93 in Thursday's regular session, versus a prior close of $41.65. The decline follows Viking pricing an upsized $500 million capital raise — 7.86 million common shares at $35 plus $225 million in 2.00% convertible senior notes due 2032.
ARTL is trading down about -32.83% intraday near $4.91 versus a $7.31 prior close, during the regular session. The decline is a sharp reversal after Wednesday's +76% close (+206% intraday) spike on its ART27.13 obesity-treatment patent filing.
SRZN surged roughly +104.7% intraday to about $33, up from a $16.16 prior close, during regular Nasdaq trading. Buying was driven by news around its SZN-8141 program, a bifunctional Wnt agonist/VEGF antagonist antibody for diabetic macular edema (DME).
ALMS is trading down -1.88% to about $7.30 during regular market hours, extending the prior session's -8.26% decline. No major company-specific headline hit today; the move reflects continued post-LUMUS selling pressure.
HOWL slipped -0.44% intraday, trading near $0.98 versus a previous close of $0.982, during regular market hours. The decline occurred on light volume (~375K shares vs. ~867K average), signaling a quiet consolidation session.
BMEA is trading down roughly -18.24% at about $1.39, versus its prior session close of $1.70, with the decline extending from premarket into Wednesday's regular session. The primary catalyst: Biomea terminated its proposed public offering of common stock and warrants, saying current market conditions were not favorable for shareholders.
JAGX is down -73.3% to roughly $9.20 during regular trading, unwinding Tuesday's +1,191% surge from $2.67 to a $34.46 close. The decline began in premarket (down about -28%) and accelerated through the session as traders took profits after FDA fiscal-2027 fee waivers for Mytesi and Canalevia-CA1.
Apnimed (APMD) is trading down about -7.88% to roughly $23.50 during regular market hours, falling from the prior session's close of $25.51. The move reflects continued profit-taking and a valuation reset following a sharp post-IPO summer rally, with no fresh company-specific negative news today.
JAGX surged roughly +825% during the regular session, climbing from a prior close of $2.67 to about $24.71 intraday. The catalyst was news that the FDA granted Napo Pharmaceuticals (a Jaguar family company) a PDUFA fee waiver for Mytesi, plus a fee waiver for Canalevia-CA1, for fiscal 2027.
CMPX is trading down about -29% to roughly $1.29 during Tuesday's regular session, after initially plunging ~40% in premarket trading. The selloff followed news that the U.S. FDA recommended Compass run an additional trial to demonstrate a survival benefit for lead asset tovecimig before submitting a marketing application.
CORT delivered robust Q2 2026 revenue growth of 32% year-over-year and raised full-year guidance amid the launch of its oncology asset. OPK shares have advanced approximately 34% year-to-date, supported by diversified operations and strategic financing moves.
Northwest Biotherapeutics (NWBO) has traded in a narrow range near $0.17 over the past 30 days, with the 30-day percentage change roughly flat at well under 10%. The stock's 52-week range spans roughly $0.14 to $0.34, reflecting the speculative nature of a pre-commercial biotechnology company.
The selected price target is $1.00 , a psychological milestone and the level typically required to satisfy Nasdaq's minimum bid price listing rule. Silexion is a clinical-stage biotech advancing SIL204, an RNA interference (RNAi) therapy for KRAS-driven pancreatic cancer, with a Phase 2/3 trial approved in Israel and Germany.
CLDX is down -17.26% to $31.35 intraday, versus a prior-session close of $37.89. The decline follows a deeper -20%+ premarket drop, driven by a classic "sell-the-news" reaction.